Skip to main content
Erschienen in: Journal of Inherited Metabolic Disease 6/2013

01.11.2013 | Original Article

High risk of primary liver cancer in a cohort of 179 patients with Acute Hepatic Porphyria

verfasst von: Eliane Sardh, Staffan Wahlin, Mikael Björnstedt, Pauline Harper, Dan E. H. Andersson

Erschienen in: Journal of Inherited Metabolic Disease | Ausgabe 6/2013

Einloggen, um Zugang zu erhalten

Abstract

Background/aims

Previous studies have indicated a high risk of hepatocellular carcinoma in acute hepatic porphyrias. In this retrospective study we present the incidence of primary liver cancer and clinical characteristics in a cohort of 179 acute porphyria patients above the age of 50 years.

Methods

Twenty-three cases with primary liver cancer were found either by a surveillance program or due to clinical suspicion. Standardized rate ratio was used to estimate the relative risk of primary liver cancer after indirect standardization. Survival data were calculated using the Kaplan-Meier method.

Results

The mean age at diagnosis was 69 years. Hepatocellular carcinoma was found in 19 patients while four patients had cholangiocarcinoma or a combination of the two. Four patients had underlying cirrhosis. Mean tumour size was 4.3 cm in the surveillance group and 10.3 cm in the non-surveillance group (p = 0.01). The overall relative risk of primary liver cancer was 86 above the age of 50: 150 for women and 37 for men. Mean survival time was 5.7 years.

Conclusion

Acute hepatic porphyria carries a high risk of primary liver cancer above the age of 50 which warrants ultrasound surveillance. Sex distribution and frequency of cirrhosis differs from more common aetiologies of primary liver cancer.
Literatur
Zurück zum Zitat Andant C, Puy H, Bogard C et al (2000) Hepatocellular carcinoma in patients with acute hepatic porphyria: frequency of occurrence and related factors. J Hepatol 32(6):933–939PubMedCrossRef Andant C, Puy H, Bogard C et al (2000) Hepatocellular carcinoma in patients with acute hepatic porphyria: frequency of occurrence and related factors. J Hepatol 32(6):933–939PubMedCrossRef
Zurück zum Zitat Anderson KE, Sassa S, Bishop DF, Desnick RJ (2001) Disorders of heme biosynthesis: X-linked sideroblastic anemia and the porphyrias. The metabolic and molecular bases of inherited disease. In: Scriver CR, Beaudet AL, Sly WS and Valle D (eds) McGraw-Hill, New York 2: 2991–3062 Anderson KE, Sassa S, Bishop DF, Desnick RJ (2001) Disorders of heme biosynthesis: X-linked sideroblastic anemia and the porphyrias. The metabolic and molecular bases of inherited disease. In: Scriver CR, Beaudet AL, Sly WS and Valle D (eds) McGraw-Hill, New York 2: 2991–3062
Zurück zum Zitat Andersson C, Bjersing L, Lithner F (1996) The epidemiology of hepatocellular carcinoma in patients with acute intermittent porphyria. J Intern Med 240:195–201PubMedCrossRef Andersson C, Bjersing L, Lithner F (1996) The epidemiology of hepatocellular carcinoma in patients with acute intermittent porphyria. J Intern Med 240:195–201PubMedCrossRef
Zurück zum Zitat Batlle AM (1993) Porphyrins, porphyrias, cancer and photodynamic therapy - a model for carcinogenesis. J Photochem Photobiol B Biol 20:5–22CrossRef Batlle AM (1993) Porphyrins, porphyrias, cancer and photodynamic therapy - a model for carcinogenesis. J Photochem Photobiol B Biol 20:5–22CrossRef
Zurück zum Zitat Bengtsson NO, Hardell L (1986) Porphyrias, porphyrins and hepatocellular cancer. Br J Cancer 54:115–117PubMedCrossRef Bengtsson NO, Hardell L (1986) Porphyrias, porphyrins and hepatocellular cancer. Br J Cancer 54:115–117PubMedCrossRef
Zurück zum Zitat Bjersing L, Andersson C, Lithner F (1996) Hepatocellular carcinoma in patients from Northern Sweden with acute intermittent porphyria: morphology and mutations. Cancer Epidemiol Biomarkers Prev 5:393–397PubMed Bjersing L, Andersson C, Lithner F (1996) Hepatocellular carcinoma in patients from Northern Sweden with acute intermittent porphyria: morphology and mutations. Cancer Epidemiol Biomarkers Prev 5:393–397PubMed
Zurück zum Zitat Bosch FX, Ribes J, Díaz M, Cléries R (2004) Primary liver cancer: worldwide incidence and trends. J Gastroenterol 127(5):S5–S16CrossRef Bosch FX, Ribes J, Díaz M, Cléries R (2004) Primary liver cancer: worldwide incidence and trends. J Gastroenterol 127(5):S5–S16CrossRef
Zurück zum Zitat Bruix J, Sherman M (2005) Management of hepatocellular carcinoma. Hepatology 42(5):1208–1236PubMedCrossRef Bruix J, Sherman M (2005) Management of hepatocellular carcinoma. Hepatology 42(5):1208–1236PubMedCrossRef
Zurück zum Zitat Deybach JC, Puy H (2011) Hepatocellular carcinoma without cirrhosis: think acute hepatic porphyrias and vice versa. J Intern Med 269(5):521–524PubMedCrossRef Deybach JC, Puy H (2011) Hepatocellular carcinoma without cirrhosis: think acute hepatic porphyrias and vice versa. J Intern Med 269(5):521–524PubMedCrossRef
Zurück zum Zitat Floderus Y, Shoolingin-Jordan P, Harper P (2002) Acute intermittent porphyria in Sweden. Molecular, functional and clinical consequences of some new mutations found in the porphobilinogen deaminase gene. Clin Genet 62(4):288–297PubMedCrossRef Floderus Y, Shoolingin-Jordan P, Harper P (2002) Acute intermittent porphyria in Sweden. Molecular, functional and clinical consequences of some new mutations found in the porphobilinogen deaminase gene. Clin Genet 62(4):288–297PubMedCrossRef
Zurück zum Zitat Hardell L, Bengtsson NO, Jonsson U, Eriksson S, Larsson LG (1984) Aetiological aspects on primary liver cancer with special regard to alcohol, organic solvents and acute intermittent porphyria - an epidemiological investigation. Br J Cancer 50:389–397PubMedCrossRef Hardell L, Bengtsson NO, Jonsson U, Eriksson S, Larsson LG (1984) Aetiological aspects on primary liver cancer with special regard to alcohol, organic solvents and acute intermittent porphyria - an epidemiological investigation. Br J Cancer 50:389–397PubMedCrossRef
Zurück zum Zitat Harper P, Wahlin S (2007) Treatment options in acute porphyria, porphyria cutanea tarda, and erythropoietic protoporphyria. Curr Treat Options Gastroenterol 10(6):444–455PubMedCrossRef Harper P, Wahlin S (2007) Treatment options in acute porphyria, porphyria cutanea tarda, and erythropoietic protoporphyria. Curr Treat Options Gastroenterol 10(6):444–455PubMedCrossRef
Zurück zum Zitat Innala E, Andersson C (2011) Screening for hepatocellular carcinoma in acute intermittent porphyria: a 15-year follow-up in northern Sweden. J Intern Med 269(5):538–545PubMedCrossRef Innala E, Andersson C (2011) Screening for hepatocellular carcinoma in acute intermittent porphyria: a 15-year follow-up in northern Sweden. J Intern Med 269(5):538–545PubMedCrossRef
Zurück zum Zitat Kauppinen R, Mustajoki P (1988) Acute hepatic porphyria and hepatocellular carcinoma. Br J Cancer 57:117–120PubMedCrossRef Kauppinen R, Mustajoki P (1988) Acute hepatic porphyria and hepatocellular carcinoma. Br J Cancer 57:117–120PubMedCrossRef
Zurück zum Zitat Kauppinen R, Mustajoki P (1992) Prognosis of acute porphyria: occurrence of acute attacks, precipitating factors, and associated diseases. Medicine 71:1–13PubMed Kauppinen R, Mustajoki P (1992) Prognosis of acute porphyria: occurrence of acute attacks, precipitating factors, and associated diseases. Medicine 71:1–13PubMed
Zurück zum Zitat Kauppinen R, von und zu Fraunberg M (2002) Molecular and biochemical studies of acute intermittent porphyria in 196 patients and their families. Clin Chem 48(11):1891–1900PubMed Kauppinen R, von und zu Fraunberg M (2002) Molecular and biochemical studies of acute intermittent porphyria in 196 patients and their families. Clin Chem 48(11):1891–1900PubMed
Zurück zum Zitat Leong TY, Leong AS (2005) Epidemiology and carcinogenesis of hepatocellular carcinoma. HPB (Oxford) 7(1):5–15CrossRef Leong TY, Leong AS (2005) Epidemiology and carcinogenesis of hepatocellular carcinoma. HPB (Oxford) 7(1):5–15CrossRef
Zurück zum Zitat Lindstedt G, Nillroth LW, von Schéele C, Schelin U, Swolin B, Zettergren L (1973) [Late first appearance of porphyria in a patient with primary liver cancer] Sen debut av porfyri hos en patient med primär levercancer. Lakartidningen 70(47):4265–4266PubMed Lindstedt G, Nillroth LW, von Schéele C, Schelin U, Swolin B, Zettergren L (1973) [Late first appearance of porphyria in a patient with primary liver cancer] Sen debut av porfyri hos en patient med primär levercancer. Lakartidningen 70(47):4265–4266PubMed
Zurück zum Zitat Lithner F, Wetterberg L (1984) Hepatocelluar carcinoma in patients with acute intermittent porphyria. Acta Med Scand 215:271–274PubMedCrossRef Lithner F, Wetterberg L (1984) Hepatocelluar carcinoma in patients with acute intermittent porphyria. Acta Med Scand 215:271–274PubMedCrossRef
Zurück zum Zitat Onuki J, Teixeira PC, Medeiros MH et al (2002) Is 5-aminolevulinic acid involved in the hepatocellular carcinogenesis of acute intermittent porphyria? Cell Mol Biol (Noisy-le-grand) 48(1):17–26 Onuki J, Teixeira PC, Medeiros MH et al (2002) Is 5-aminolevulinic acid involved in the hepatocellular carcinogenesis of acute intermittent porphyria? Cell Mol Biol (Noisy-le-grand) 48(1):17–26
Zurück zum Zitat Ostrowski J, Kostrzewska E, Michalak T, Zawirska B, Medrzejewski W, Gregor A (1983) Abnormalities in liver function and morphology and impaired aminopyrine metabolism in hereditary hepatic porphyrias. Gastroenterology 85:1131–1137PubMed Ostrowski J, Kostrzewska E, Michalak T, Zawirska B, Medrzejewski W, Gregor A (1983) Abnormalities in liver function and morphology and impaired aminopyrine metabolism in hereditary hepatic porphyrias. Gastroenterology 85:1131–1137PubMed
Zurück zum Zitat Schneider-Yin X, Van Tuyll van Serooskerken AM, Went P et al (2010) Hepatocellular carcinoma in variegate porphyria: a serious complication. Acta Derm Venereol 90(5):512–515PubMedCrossRef Schneider-Yin X, Van Tuyll van Serooskerken AM, Went P et al (2010) Hepatocellular carcinoma in variegate porphyria: a serious complication. Acta Derm Venereol 90(5):512–515PubMedCrossRef
Zurück zum Zitat Seth AK, Badminton MN, Mirza D, Russell S, Elias E (2007) Liver transplantation for porphyria: who, when, and how? Liver Transpl 13(9):1219–1227PubMedCrossRef Seth AK, Badminton MN, Mirza D, Russell S, Elias E (2007) Liver transplantation for porphyria: who, when, and how? Liver Transpl 13(9):1219–1227PubMedCrossRef
Zurück zum Zitat Soonawalla ZF, Orug T, Badminton MN et al (2004) Liver transplantation as a cure for acute intermittent porphyria. Lancet 363(9410):705–706PubMedCrossRef Soonawalla ZF, Orug T, Badminton MN et al (2004) Liver transplantation as a cure for acute intermittent porphyria. Lancet 363(9410):705–706PubMedCrossRef
Zurück zum Zitat Stojeba N, Meyer C, Jeanpierre C et al (2004) Recovery from a variegate porphyria by a liver transplantation. Liver Transpl 10(7):935–938PubMedCrossRef Stojeba N, Meyer C, Jeanpierre C et al (2004) Recovery from a variegate porphyria by a liver transplantation. Liver Transpl 10(7):935–938PubMedCrossRef
Zurück zum Zitat Thunell S, Andersson C, Carlmark B et al (1995) Markers for vulnerability in acute porphyria. A hypothesis paper. Eur J Clin Chem Clin Biochem 33:179–194PubMed Thunell S, Andersson C, Carlmark B et al (1995) Markers for vulnerability in acute porphyria. A hypothesis paper. Eur J Clin Chem Clin Biochem 33:179–194PubMed
Zurück zum Zitat Thunell S, Floderus Y, Henrichson A, Harper P (2006) Porphyria in Sweden. Physiol Res 55(Suppl 2):S109–S118PubMed Thunell S, Floderus Y, Henrichson A, Harper P (2006) Porphyria in Sweden. Physiol Res 55(Suppl 2):S109–S118PubMed
Zurück zum Zitat Wahlin S, Harper P, Sardh E, Andersson C, Andersson DE, Ericzon BG (2010) Combined liver and kidney transplantation in acute intermittent porphyria. Transpl Int 23(6):e18–e21PubMedCrossRef Wahlin S, Harper P, Sardh E, Andersson C, Andersson DE, Ericzon BG (2010) Combined liver and kidney transplantation in acute intermittent porphyria. Transpl Int 23(6):e18–e21PubMedCrossRef
Zurück zum Zitat Wiman Å (2003) Genetic Characterization of Swedish Families with Hereditary Coproporphyria, Variegate Porphyria, and Erythropoietic Protoporphyria. Dep Med Lab Sci and Tech, Div Clin Chem, Karolinska Institutet, Huddinge Univ Hospital. Stockholm, Karolinska Institutet Wiman Å (2003) Genetic Characterization of Swedish Families with Hereditary Coproporphyria, Variegate Porphyria, and Erythropoietic Protoporphyria. Dep Med Lab Sci and Tech, Div Clin Chem, Karolinska Institutet, Huddinge Univ Hospital. Stockholm, Karolinska Institutet
Metadaten
Titel
High risk of primary liver cancer in a cohort of 179 patients with Acute Hepatic Porphyria
verfasst von
Eliane Sardh
Staffan Wahlin
Mikael Björnstedt
Pauline Harper
Dan E. H. Andersson
Publikationsdatum
01.11.2013
Verlag
Springer Netherlands
Erschienen in
Journal of Inherited Metabolic Disease / Ausgabe 6/2013
Print ISSN: 0141-8955
Elektronische ISSN: 1573-2665
DOI
https://doi.org/10.1007/s10545-012-9576-9

Weitere Artikel der Ausgabe 6/2013

Journal of Inherited Metabolic Disease 6/2013 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Perioperative Checkpointhemmer-Therapie verbessert NSCLC-Prognose

28.05.2024 NSCLC Nachrichten

Eine perioperative Therapie mit Nivolumab reduziert das Risiko für Rezidive und Todesfälle bei operablem NSCLC im Vergleich zu einer alleinigen neoadjuvanten Chemotherapie um über 40%. Darauf deuten die Resultate der Phase-3-Studie CheckMate 77T.

Positiver FIT: Die Ursache liegt nicht immer im Dickdarm

27.05.2024 Blut im Stuhl Nachrichten

Immunchemischer Stuhltest positiv, Koloskopie negativ – in solchen Fällen kann die Blutungsquelle auch weiter proximal sitzen. Ein Forschungsteam hat nachgesehen, wie häufig und in welchen Lokalisationen das der Fall ist.

GLP-1-Agonisten können Fortschreiten diabetischer Retinopathie begünstigen

24.05.2024 Diabetische Retinopathie Nachrichten

Möglicherweise hängt es von der Art der Diabetesmedikamente ab, wie hoch das Risiko der Betroffenen ist, dass sich sehkraftgefährdende Komplikationen verschlimmern.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.